tpt_8k
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report: August 6, 2020
TPT Global Tech, Inc.
(Exact name of registrant as specified in its charter)
|
Florida
|
|
333-222094
|
|
81-3903357
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification Number)
|
501 West Broadway, Suite 800, San Diego, CA 92101
(Address of Principal Executive Offices) (Zip Code)
(619)301-4200
Registrant's telephone number, including area code
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
None
|
Title of each Class
|
Trading Symbol
|
Name of each exchange on which registered
|
|
N/A
|
N/A
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter)
Emerging Growth Company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement
On August 6, 2020, TPT MedTech, LLC, a subsidiary of TPT Global
Tech, Inc., signed a binding letter of intent with Rennova Health,
Inc.(“Rennova”) to acquire EPIC Reference Labs, Inc.
(“EPIC”), wholly owned subsidiary of Rennova, for
$750,000, comprised of a deposit of $25,000 within five days of
signing and the remainder due either from 20% of net proceeds
received from fund raising that the Company has initiated and as
evidence by SEC Filings or a minimum payment of $25,000 per month
until paid in full. The first $25,000 payment has been made. All
defined laboratory equipment and a $100,000 lease deposit were
excluded from the sales price. All liabilities incurred up to
signing are to be discharged. Receivables existing at signing are
to be 100% ownership of Rennova. There are no other significant
assets. This acquisition will allow TPT MedTech, LLC to own a
license to operate medical testing facilities.
EPIC is a high complexity clinical laboratory located in West Palm
Beach, Florida. The binding letter of intent includes EPIC’s
current CLIA certificate of registration that enables TPT
MedTech’s Mobile QuikLabs to operate in 46 US States
delivering rapid Covid-19 Point-of-Care testing and monitoring.
Closing of the acquisition is subject to normal change of ownership
application and notification to certain regulatory and licensing
bodies. Until the change of ownership is complete, Rennova will
operate the laboratory under agreement on behalf of TPT MedTech,
LLC.
Item 7.01 Regulation FD Disclosure.
Press Release
The information in this Item 7.01 of this Current Report is
furnished pursuant to Item 7.01 and shall not be deemed "filed" for
any purpose, including for the purposes of Section 18 of the
Exchange Act, or otherwise subject to the liabilities of that
Section. The information in this Current Report on Form 8-K shall
not be deemed incorporated by reference into any filing under the
Securities Act or the Exchange Act regardless of any general
incorporation language in such filing.
On August 21, 2020, the Company issued a press release entitled
“TPT Global Tech's Mobile COVID-19 "QuikLAB(TM)" and Its
"Aire Fitness" Mobile Gym In Transit To Their New Homes In Texas
and
Miami.” A copy
of the press release is attached hereto as Exhibit
99.1.
On August 25, 2020, the Company issued a press release entitled
“TPT Global Tech's Signs Distribution Agreement with All Star
Health Brands for Sales & Marketing of QuikLAB Rapid Covid-19
Testing Labs.” A copy of the press release is attached hereto
as Exhibit 99.2.
On August 31, 2020, the Company issued a press release entitled
“TPT Global Tech's CEO Stephen Thomas "QuikLAB and SaniQuik"
Airs on Fox 32 Chicago.” A copy of the press release is
attached hereto as Exhibit 99.3.
On September 4, 2020, the Company issued a press release entitled
“TPT Global Tech, Inc. Acquires Clinical Laboratory In West
Palm Beach, Florida To Facilitate Immediate Operation Of Its Mobile
"QuikLABs" In Florida.” A copy of the press release is
attached hereto as Exhibit 99.4.
Item 9.01 Exhibits
The following exhibits are filed with this report on Form
8-K.
|
Exhibit Number
|
|
Exhibit
|
|
|
|
Letter
of Intent between Medytox Diagnostics, Inc., EPIC Reference Labs,
Inc. and Rennova Health, Inc. and TPT MedTech, LLC dated August 6,
2020
|
|
|
|
Interim
Management Agreement effective August 6, 2020
|
|
|
|
Press
Release dated August 21, 2020
|
|
|
|
Press
Release dated August 25, 2020
|
|
|
|
Press
Release dated August 31, 2020
|
|
|
|
Press
Release dated September 4, 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned, hereunto duly
authorized.
|
|
TPT GLOBAL TECH, INC.
|
|
|
|
|
|
|
|
Date:
September 9, 2020
|
By:
|
/s/ Stephen
J. Thomas III,
|
|
|
|
Name:
|
Stephen
J. Thomas III,
|
|
|
|
Title:
|
Chief
Executive Officer
|
|
